CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Fingolimod +1 moredrug
Likely dose
Fingolimod 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01779700
NCT01779700Phase 2Completed
CompareCT.gov

Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment

Indiana University·interventional·Posted Jan 30, 2013·Updated Apr 16, 2019

In Brief

A Phase 2 clinical trial evaluating Fingolimod and placebo for Schizophrenia. Completed, enrolled 40 participants across 3 sites.

Detailed Summary

This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 30, 2013
Enrollment StartJan 1, 2013
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.4 years ago

Interventions

Fingolimoddrug

0.5mg each day of 8 week cycle

placebodrug

1 tablet each day of 8 week cycle